In a report released today, Gaurav Goparaju from Berenberg Bank maintained a Buy rating on Recursion Pharmaceuticals (RXRX – Research Report), with a price target of $33.00. The company’s shares closed yesterday at $8.55.
According to TipRanks, Goparaju is an analyst with an average return of -20.1% and a 30.00% success rate. Goparaju covers the Technology sector, focusing on stocks such as Schrodinger, Berkeley Lights, and Certara.
Recursion Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $16.67.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $14.18 and a one-year low of $4.92. Currently, Recursion Pharmaceuticals has an average volume of 1.26M.
Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RXRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Read More on RXRX:
